← Companies|Hikma Pharma
HI

Hikma Pharma

HIK.L·LSELondon UKFounded 19788,500 employees
Mid CappharmaPublicInfectious DiseaseOncology
Platform: Injectable Gen
Market Cap
$5B
All Drugs
3
Clinical Trials
4
Failed / Terminated
1
FDA Approved
0
Stock Price & Catalysts (HIK.L)
Loading HIK.L stock data...
Drug Pipeline (3 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
RimanaritideHIK-1049Phase 2/31Gene TherapyCDK4/6PCSK9iNASHHS
GeliderotideHIK-1408Phase 22Small MoleculeSMN2PRMT5iCholangiocarcinomaLN
HIK-6819HIK-6819Preclinical1Fusion ProteinTIM-3USP1iWet AMD
SEC Filings & Financial Documents
SEC filings are not available for LSE-listed companies.
Hikma Pharma trades on LSE (GB). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (4)
2025-12-14
Rimanaritide Ph1 Dose Esc
HS
Past
2028-06-23
Rimanaritide Ph3 Readout
NASH
Ph3 Readout
2031-01-25
Geliderotide Ph2 Data
RCC
Ph2 Data
2031-05-02
HIK-6819 Interim
Wet AMD
Interim